Discounted measles vaccination costs, cases, treatment costs, net costs, DALYS averted and cost per DALY averted in 2018 US$ over 2018–2047, 93 LMICs
| Discounted measles vaccination costs, treatment costs, net costs and DALYs averted | |||||
| Scenario | Discounted* vaccination costs (millions) | Cases (millions) | Measles treatment costs (millions) | DALYs (millions) | Total costs (millions) |
| Base Case | US$10 459 | 490.4 | US$10 014 | 783 | US$20 473 |
| Continuing Trends | US$11 918 | 213.8 | US$6158 | 332 | US$18 076 |
| Constant Improvement | US$13 857 | 158.0 | US$4724 | 230 | US$18 580 |
| Intensified Investment | US$14 794 | 111.5 | US$3537 | 158 | US$18 332 |
| Cost per DALY averted | |||||
| Scenario | Comparator | Net costs (millions) | DALYs averted (millions) | Cost per DALY averted | Percentage of countries meeting Ochalek threshold |
| Continuing Trends | Base Case | −US$2397 | 451 | Dominant | 89 |
| Constant Improvement | Continuing Trends | US$505 | 102 | US$4.94 | 76 |
| Intensified Investment | Continuing Trends | US$256 | 174 | US$1.47 | 70 |
| Intensified Investment | Constant Improvement | −US$249 | 72 | Dominant | 80 |
*The costs were discounted with a discount rate of 3%. Note: The cost-effectiveness threshold for the 92 LMICs, were estimated based on cost per DALYs averted that reflect health opportunity costs on mortality of changes in health expenditures.13
DALYs, disability-adjusted life years ; LMICs, low-income and middle-income countries.